Wei et al.

Additional file 2.

Table S1. Clinical features and CD44 variant expression in the CHOP and R-CHOP groups.

Characteristics	N	CHOP		R-CHOP		P
		n	%	n	%	
Gender						0.380
Female	50	25	47.2	25	39.1	
Male	67	28	52.8	39	60.1	
Age(years)						0.487
<60y	71	34	64.2	37	57.8	
≥60y	46	19	35.8	27	42.2	
Systemic symptoms						0.360
A	78	33	62.3	45	70.3	
B	39	20	37.3	19	29.7	
BM involvement						0.004
Yes	22	16	30.2	6	9.4	
No	95	37	69.8	58	90.6	
LDH levels						0.015
Normal	71	26	47.2	45	70.3	
High	46	27	52.8	19	29.7	
Ann Arbor stage						0.884
I or II	45	20	37.3	25	39.1	
III or IV	72	33	62.3	39	60.9	
No. of extranodal sites						0.498
0-1	81	35	66.0	46	71.9	
≥2	36	18	34.0	18	28.1	
IPI score						0.104
0-1	54	20	37.7	34	53.1	
2	26	13	24.5	13	20.3	
3	18	7	13.2	11	17.2	
4-5	19	13	24.5	6	9.4	
COO subtype						0.707
GCB	42	20	37.7	22	34.4	
NON-GCB	75	33	62.3	42	65.6	
CD44H						0.243
-	42	16	30.2	26	40.6	
+	75	37	69.8	38	59.4	
CD44v6						0.261
-	77	32	60.4	45	70.3	
+	40	21	39.6	19	29.7	

Mann-Whitney U test was applied to assess the difference in distribution between the CHOP and R-CHOP groups.

Additional file 2.

Table S2.Patient characteristics according to CD44H and CD44v6 expression status.

Characteristics	n	CD44H —	CD44H +	P	CD44v6 —	CD44v6 +	P
Gender				0.173			0.113
Female	53(44.2%)	15	38		39	14	
Male	67(55.8%)	27	40		40	27	
Age(years)				0.276			0.309
<60y	72(60.0%)	28	44		50	22	
≥60y	48(40.0%)	14	34		29	19	
Systemic symptoms				0.887			0.782
A	81(67.5%)	28	53		54	27	
B	39(32.5%)	14	25		25	14	
IPI score				0.130			0.642
0-2	83(72.5%)	33	50		55	28	
3-5	37(27.5%)	9	28		24	13	
Bone marrow involvement				0.014			0.365
Yes	23(19.2%)	3	20		17	6	
No	97(80.8%)	39	58		62	35	
Lactate dehydrogenase				0.218			0.193
Normal	74(61.7%)	29	45		52	22	
High	46(38.3%)	13	33		27	19	
Ann Arbor stage				0.756			0.309
or	48(40.0%)	16	32		29	19	
or	72(60.0%)	26	46		50	22	
No. of extranodal sites				0.421			0.273
0-1	83(69.2%)	31	52		52	31	
≥2	37(30.8%)	11	26		27	10	
Cell-of-origin subtype				0.116			0.499
GCB	43(35.8%)	19	24		30	13	
NON-GCB	77(64.2%)	23	54		49	28	
Treatment				0.243			0.261
CHOP	53(44.2%)	16	37		32	21	
R-CHOP	64(53.3%)	26	38		45	19	

Note: Three patients that were treated with therapies other than CHOP and R-CHOP were included in this table but excluded from the prognostic studies.

Additional file 2.

Table S3.Prognostic factors and multivariable survival analysis.

Prognostic factors	Multivariable analysis		
	RR	95%CI	*P*
Analysis of the entire cohort(n=117)			
Overall survival			
IPI (High:3~5 vs Low:0~2)	2.9	2.0-4.1	**<0.001**
CD44H (PosvsNeg)	1.3	0.48-3.4	0.618
CD44v6 (PosvsNeg)	2.4	1.2-4.7	**0.017**
Event-free survival			
IPI (High:3~5 vs Low:0~2)	2.4	1.8-3.3	**<0.001**
CD44H (Pos vs Neg)	1.1	0.47-2.5	0.861
CD44v6 (Pos vs Neg)	2.2	1.1-4.1	**0.019**
Analysis of the CHOP group (n=53)			
Overall survival			
IPI (High:3~5 vs Low:0~2)	2.6	1.7-4.0	**<0.001**
CD44H (PosvsNeg)	0.93	0.25-3.4	0.909
CD44v6 (PosvsNeg)	2.1	0.9-5.3	0.098
Event-free survival			
IPI (High:3~5 vs Low:0~2)	2.5	1.7-3.8	**<0.001**
CD44H (PosvsNeg)	0.76	0.22-2.6	0.664
CD44v6 (PosvsNeg)	2.1	0.87-5.2	0.096
Analysis of the R-CHOP group (n=64)			
Overall survival			
IPI (High:3~5 vs Low:0~2)	2.9	1.5-5.5	**0.002**
CD44H (PosvsNeg)	1.6	0.3-8.7	0.579
CD44v6 (PosvsNeg)	2.3	0.6-8.5	0.226
Event-free survival			
IPI (High:3~5 vs Low:0~2)	2.0	1.5-4.5	**0.003**
CD44H (PosvsNeg)	1.3	0.38-4.4	0.691
CD44v6 (PosvsNeg)	2.0	0.69-5.9	0.201